These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7330645)

  • 1. [Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency].
    Dayer P; Glasson P; Gorgia A; Balant L; Fabre J
    Schweiz Med Wochenschr; 1981 Dec; 111(49):1915-8. PubMed ID: 7330645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
    Balant L; Gorgia A; Marmy A; Tschopp JM
    Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of age on the pharmacokinetics of oxprenolol.
    Kendall MJ; Quarterman CP
    Int J Clin Pharmacol Ther Toxicol; 1982 Mar; 20(3):101-4. PubMed ID: 7068281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction to the topic: drug dosage in renal insufficiency].
    Sieberth HG
    Internist (Berl); 1981 Oct; 22(10):597-600. PubMed ID: 7028661
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacokinetic and biological effective time of beta-receptor blockers in renal insufficiency].
    Knauf H; Schäfer-Korting M; Mutschler E
    Internist (Berl); 1981 Oct; 22(10):616-21. PubMed ID: 6117538
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics in patients with renal failure.
    Maher JF
    Clin Nephrol; 1984 Jan; 21(1):39-46. PubMed ID: 6368069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Digitalis glycosides and renal insufficiency].
    Grabensee B; Peters U; Risler T
    Internist (Berl); 1981 Oct; 22(10):622-8. PubMed ID: 7028664
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug dosing guidelines in patients with renal failure.
    Swan SK; Bennett WM
    West J Med; 1992 Jun; 156(6):633-8. PubMed ID: 1615656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of chronic renal insufficiency on the demethylating activities of various cytochrome P-450 subspecies in humans].
    Simon HU; Günther K; Balogh A; Ortweiler W; Splinter FK; Stein G; Traeger A
    Pharmazie; 1985 Nov; 40(11):790-2. PubMed ID: 4095132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy in renal failure].
    Lachhein L
    Z Gesamte Inn Med; 1980 Aug; 35(15):Suppl 38-40. PubMed ID: 7467564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Altered pharmacokinetics and dosage of antirheumatics, corticosteroids, cytostatics and immunosuppressives in renal insufficiency].
    Vlaho M; Gross R
    Internist (Berl); 1981 Oct; 22(10):629-35. PubMed ID: 7028665
    [No Abstract]   [Full Text] [Related]  

  • 15. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
    Racine-Poon A; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of diuretics and antihypertensives in renal insufficiency].
    Kindler J; Schulz V
    Internist (Berl); 1981 Oct; 22(10):607-15. PubMed ID: 7028663
    [No Abstract]   [Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
    Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
    J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans.
    Laethem ME; Lefebvre RA; Belpaire FM; Vanhoe HL; Bogaert MG
    Clin Pharmacol Ther; 1995 Apr; 57(4):419-24. PubMed ID: 7712670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug prescribing in children with renal failure.
    Moudgil A; Srivastava RN
    Indian Pediatr; 1989 Jul; 26(7):693-705. PubMed ID: 2684862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.